Search Results - "Larrayoz, M. A."

Copy Number Alterations Suggest a Functional Switch from Innate Immunity to DNA Repair and Drive Clinical Heterogeneity in Plasma Cell Dyscrasias.

Authors: Barreto, Igor Valentim Ferreira, Wallax Augusto Silva Morais, Guilherme Passos de et al.

Source: International Journal of Translational Medicine. Jun2026, Vol. 6 Issue 2, p21. 21p.

Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.

Authors: Jang, Ho Cheol Song, Ga-Young Jeong, Hyeonjin et al.

Source: International Journal of Molecular Sciences. Mar2026, Vol. 27 Issue 6, p2610. 14p.

Elevated Allele Frequency of a Common Germline LAG3 Variant Associated with Anemia, Thrombocytopenia and Peripheral Blast Percentage in Acute Myeloid Leukemia.

Authors: Seipel, Katja Shaforostova, Inna Tarozzi, Elisa et al.

Source: Cancers. May2026, Vol. 18 Issue 10, p1671. 12p.

Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics.

Authors: Muiños-Lopez, Emma Lopez-Perez, Ana Rosa Sudupe, Laura et al.

Source: Communications Biology. 11/20/2025, Vol. 8 Issue 1, p1-15. 15p.

Targeting CDK11 in Rhabdoid Tumor of the Kidney.

Authors: Murakami, Yuki Lam, Kamhung Fukui, Shinsuke et al.

Source: Cancers. Jan2026, Vol. 18 Issue 2, p261. 12p.

Functional Intraclonal Heterogeneity in Chronic Lymphocytic Leukemia: Proliferation vs. Quiescence.

Authors: Friedman, Daniel Patten, Piers E. M. Hoogeboom, Robbert

Source: Lymphatics. Dec2025, Vol. 3 Issue 4, p47. 8p.

Complex TP53 Alterations with del(17p) and del(13q) in Chronic Lymphocytic Leukemia: Clinical Implications from a Case-Based Review.

Authors: Balla, Beata Crauciuc, Andrei Lazar, Erzsebet et al.

Source: International Journal of Molecular Sciences. Jul2026, Vol. 27 Issue 13, p5843. 18p.

Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy.

Authors: Fenouille, Nina Lobry, Camille Benajiba, Lina et al.

Source: Oncogenesis. 5/7/2026, Vol. 15 Issue 1, p1-18. 18p.

Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospects.

Authors: Wu, Jun Dong, Haibo Xu, Xuejing et al.

Source: Leukemia & Lymphoma. May2026, Vol. 67 Issue 6, p1231-1246. 16p.

Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner.

Authors: Zhang, Tianzhuo Wei, Danna Zhan, Yun et al.

Source: Cancer Cell International. 4/4/2025, Vol. 25 Issue 1, p1-12. 12p.

PF-04691502, a PI3K/mTOR Dual Inhibitor, Ameliorates AD-like Pathology in a Mouse Model of AD.

Authors: Lanza, Marika Basilotta, Rossella Caccamo, Antonella et al.

Source: Cells (2073-4409). Sep2025, Vol. 14 Issue 18, p1474. 19p.

ON MODELLING OF THREE DIMENSIONAL FLOW IN EXTRACTION OF BIOLOGICALLY ACTIVE SUBSTANCES FROM PLANTS.

Authors: Strautins, Uldis Marinaki, Maksims

Source: Engineering for Rural Development - International Scientific Conference. 2023, p204-209. 6p.

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma.

Authors: Zhou, Qiaolin Xu, Fang Wen, Jingjing et al.

Source: Cancer Medicine. Jun2025, Vol. 14 Issue 11, p1-9. 9p.

T-lymphocytes suppression by CD14⁺ monocytes with high expression of ULK2 in patients with multiple myeloma.

Authors: Peng, Fengping Liu, Zhaoyun Jiang, Fengjuan et al.

Source: Journal of Translational Medicine. 5/7/2025, Vol. 23 Issue 1, p1-14. 14p.

PI3K/mTOR Signaling Pathway Dual Inhibition for the Management of Neuroinflammation: Novel Insights from In Vitro Models.

Authors: Ardizzone, Alessio Scuderi, Sarah Adriana Casili, Giovanna et al.

Source: Biomolecules (2218-273X). May2025, Vol. 15 Issue 5, p677. 16p.

Investigation of Point-Contact Strategies for CFD Simulations of Pebble-Bed Reactor Cores.

Authors: Goth, Nolan Nguyen, Thien Pointer, William David

Source: Applied Sciences (2076-3417); Aug2024, Vol. 14 Issue 16, p7343, 19p

Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.

Authors: Ghiță, Alina Ioana Silberschmidt, Vadim V. Ioniță, Mariana

Source: International Journal of Molecular Sciences. Apr2026, Vol. 27 Issue 8, p3611. 31p.

Treatment of a Patient with Acute Promyelocytic Leukemia with Multiple Isolated Relapses in the Central Nervous System: A Case Report and Mini-Review of the Literature.

Authors: Sun, Qixin Chen, Wenyi Wang, Ahui et al.

Source: Case Reports in Hematology. 5/3/2024, Vol. 2024, p1-5. 5p.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Authors: Raponi, Sara Del Giudice, Ilaria Ilari, Caterina et al.

Source: Angewandte Chemie. Apr2019, Vol. 131 Issue 15, p156-159. 4p.

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.

Authors: Muylaert, Catharina Van Hemelrijck, Lien Ann Van der Vreken, Arne et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 4/17/2025, Vol. 44 Issue 1, p1-18. 18p.